JP2023536596A5 - - Google Patents
Info
- Publication number
- JP2023536596A5 JP2023536596A5 JP2023507275A JP2023507275A JP2023536596A5 JP 2023536596 A5 JP2023536596 A5 JP 2023536596A5 JP 2023507275 A JP2023507275 A JP 2023507275A JP 2023507275 A JP2023507275 A JP 2023507275A JP 2023536596 A5 JP2023536596 A5 JP 2023536596A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- baffr antibody
- conjugated fragment
- lymphoma
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060786P | 2020-08-04 | 2020-08-04 | |
| US63/060,786 | 2020-08-04 | ||
| US202063114363P | 2020-11-16 | 2020-11-16 | |
| US63/114,363 | 2020-11-16 | ||
| US202163147507P | 2021-02-09 | 2021-02-09 | |
| US63/147,507 | 2021-02-09 | ||
| PCT/US2021/044113 WO2022031567A1 (en) | 2020-08-04 | 2021-08-02 | Treatment of b cell malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536596A JP2023536596A (ja) | 2023-08-28 |
| JP2023536596A5 true JP2023536596A5 (cg-RX-API-DMAC10.html) | 2024-08-13 |
| JP7834711B2 JP7834711B2 (ja) | 2026-03-24 |
Family
ID=77448106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507275A Active JP7834711B2 (ja) | 2020-08-04 | 2021-08-02 | Ｂ細胞悪性腫瘍の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230279132A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4192869A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7834711B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230042594A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116133687A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021320129B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3190678A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL300086A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202221033A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022031567A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83458C2 (uk) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| AU2009272771B2 (en) | 2008-07-17 | 2012-09-20 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| CA3160207A1 (en) * | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
-
2021
- 2021-08-02 JP JP2023507275A patent/JP7834711B2/ja active Active
- 2021-08-02 AU AU2021320129A patent/AU2021320129B2/en active Active
- 2021-08-02 KR KR1020237007141A patent/KR20230042594A/ko active Pending
- 2021-08-02 CA CA3190678A patent/CA3190678A1/en active Pending
- 2021-08-02 WO PCT/US2021/044113 patent/WO2022031567A1/en not_active Ceased
- 2021-08-02 CN CN202180062994.8A patent/CN116133687A/zh active Pending
- 2021-08-02 EP EP21758931.6A patent/EP4192869A1/en active Pending
- 2021-08-02 IL IL300086A patent/IL300086A/en unknown
- 2021-08-02 TW TW110128346A patent/TW202221033A/zh unknown
- 2021-08-04 US US18/019,469 patent/US20230279132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11712468B2 (en) | CD70 combination therapy | |
| RU2625222C2 (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| US11224654B2 (en) | Combinations and uses thereof | |
| TWI865644B (zh) | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 | |
| JP7704748B2 (ja) | 逐次抗ｃｄ１９治療 | |
| JP2014525926A5 (cg-RX-API-DMAC10.html) | ||
| JP2015517511A (ja) | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 | |
| JP2022523763A (ja) | キメラ抗原受容体を発現する細胞とモノクローナル抗体との組み合わせを用いたがん免疫療法 | |
| US20250114456A1 (en) | Enhanced immunotherapeutic method comprising combined administration of photodynamic / radiotherapeutic compounds and immunotherapeutic agents | |
| CA3117282C (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| IL300086A (en) | Treatment of B-cell malignancies | |
| HK40097470A (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| CN120346313A (zh) | 治疗肿瘤的药物组合 | |
| HK40052961A (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| HK40052961B (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| EA051578B1 (ru) | Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы | |
| EA049354B1 (ru) | Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза |